Phase III timing in a later disclosure
This 27 May 2026 article retains its original reference to an upcoming Phase III study. The company’s 25 August 2026 interim results announcement subsequently reported that enrollment in the Chinese Phase III study in adult obesity and overweight had been completed in November 2025, with 30-week follow-up for the primary efficacy endpoint completed in July 2026. Consult the later dated disclosure for current development progress.
Original report · translated from Chinese
Shanghai, China, 27 May 2026 — Innogen (HKEX: 02591), a biopharmaceutical company focused on developing and commercialising innovative metabolic medicines, announced plans to present Chinese Phase IIb clinical data for efsubaglutide alfa at the 2026 American Diabetes Association (ADA) Scientific Sessions, taking place in New Orleans, United States, on 5–8 June 2026.
Innogen’s presentation details:
Efsubaglutide alfa poster
Title: Efsubaglutide alfa in overweight or obesity: the Phase IIb ENLIGHT study
English title: Efsubaglutide Alfa in Overweight or Obesity: Phase IIb ENLIGHT Study
Abstract number: 2636-P
Time: 8 June 2026, 12:30 PM, US Central Time
Presenter: Dr Qinghua Wang, founder, Chairman and CEO of Innogen
The Chinese Phase IIb ENLIGHT study of internally developed efsubaglutide alfa met its primary endpoint, according to topline results. The randomised, double-blind, placebo-controlled multicentre study enrolled 200 adults with overweight or obesity without diabetes and evaluated efficacy and safety over 18 weeks across doses of 5–20 mg. All dose groups showed significant reductions in body weight from baseline compared with placebo. Weight loss increased with dose, and weight continued to decline during treatment without an observed plateau.
Doses associated with the ENLIGHT results
The ADA 2026 abstract reports 18-week weight reductions of 10.58% with 20 mg once weekly and 9.70% with 20 mg every two weeks. Other weekly doses were also studied, but these figures apply to those two dose groups. The obesity indication and these dosing regimens remain investigational.
The study used a simple, rapid titration schedule, increasing doses every two weeks to reach 20 mg within six weeks, with weekly and every-two-weeks administration. After 18 weeks including titration and maintenance, weight reductions were 10.58% in the weekly group and 9.70% in the every-two-weeks group. Waist circumference, visceral fat and liver fat also improved significantly. The article reports that weight loss was predominantly fat rather than muscle, increasing the muscle-to-fat ratio by 45.3%, while liver fat fell by 46.9%. No hypoglycaemic events occurred during treatment. Gastrointestinal adverse reactions were mainly mild or moderate, transient and self-resolving.
Dr Wang described the Phase IIb results scheduled for presentation at ADA as encouraging. He said the Chinese-developed long-acting agonist’s molecular design supported substantial weight loss and ‘fat reduction with muscle preservation’, with differentiated potential, good tolerability and convenient administration. He viewed the data as strong support for its obesity-development prospects and the forthcoming Phase III study, and said the company would accelerate further research to bring the innovation to patients in China and internationally.
This content communicates company research developments and industry information; it is not a pharmaceutical advertisement, treatment recommendation or promise of efficacy. Prescription medicines should be purchased with a physician’s prescription and used under medical supervision.
About Innogen
Founded in 2014, Innogen (HK.2591) is a biopharmaceutical company focused on developing and commercialising innovative medicines for metabolic diseases. Its internally developed pipeline covers indications including type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer’s disease (AD), with international intellectual-property rights and a global patent strategy. Its core product, efsubaglutide alfa, is an internally developed, next-generation human-derived ultra-long-acting GLP-1 receptor agonist approved for type 2 diabetes in the Chinese mainland and Macao, China. It is included in the National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List (2025). The product has entered international development and registration, with the aim of providing better treatment options to patients worldwide. For more information, visit www.innogenpharm.com.